Abstract | PURPOSE: METHODS: RESULTS: Twenty-one patients were enrolled. No dose-limiting toxicities were observed in the phase I study and oral curcumin 8 g/day was selected as the recommended dose for the phase II study. No patients were withdrawn from this study because of the intolerability of curcumin, which met the primary endpoint of the phase II study, and the median compliance rate of oral curcumin was 100% (Range 79-100%). Median survival time after initiation of curcumin was 161 days (95% confidence interval 109-223 days) and 1-year survival rate was 19% (4.4-41.4%). Plasma curcumin levels ranged from 29 to 412 ng/ml in five patients tested. CONCLUSIONS:
|
Authors | Masashi Kanai, Kenichi Yoshimura, Masanori Asada, Atsushi Imaizumi, Chihiro Suzuki, Shigemi Matsumoto, Takafumi Nishimura, Yukiko Mori, Toshihiko Masui, Yoshiya Kawaguchi, Kazuhiro Yanagihara, Shujiro Yazumi, Tsutomu Chiba, Sushovan Guha, Bharat B Aggarwal |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 68
Issue 1
Pg. 157-64
(Jul 2011)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 20859741
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Drug Combinations
- Deoxycytidine
- S 1 (combination)
- Tegafur
- Oxonic Acid
- Curcumin
- Gemcitabine
|
Topics |
- Adenocarcinoma
(drug therapy, mortality, physiopathology)
- Aged
- Antineoplastic Agents
(administration & dosage, adverse effects, blood, pharmacokinetics)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Curcumin
(administration & dosage, adverse effects, pharmacokinetics)
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives)
- Drug Combinations
- Drug Resistance, Neoplasm
- Drug Synergism
- Female
- Humans
- Male
- Medication Adherence
- Middle Aged
- Oxonic Acid
(adverse effects, therapeutic use)
- Pancreatic Neoplasms
(drug therapy, mortality, physiopathology)
- Survival Rate
- Tegafur
(adverse effects, therapeutic use)
- Gemcitabine
|